Mounting evidence suggests that FDA-approved weight loss medications, such as Wegovy, not only help patients lose weight but also protect against complications from obesity such as cardiovascular disease. […]
UK organisations responsible for protecting the public from prescription-only drug adverts are putting patients at risk from the harms of weight loss drugs by not enforcing the law, […]
Data from a “real world” study indicates that treatment with the semaglutide (Ozempic/Wegovy) for type 2 diabetes significantly improves both blood sugar control and weight loss for up […]
Deborah Evans is Superintendent Pharmacist and Clinic Director at Remedi Health, where she runs a weight management service, including the provision of semaglutide. In this series of short […]
People seeking semaglutide for weight management from a pharmacy-led service need to feel assured that the service is ethical and legal and has the best interests of the […]
Taking time to understand a patient’s weight loss goals and checking their medical history to ensure there are no underlying problems that may need onward referral are both […]
Online supply of semaglutide makes the medicine more accessible but may not provide the best support or guidance to enable people to get the best out of the […]
Wegovy and Ozempic both contain semaglutide but are authorised for different indications. They are also presented in slightly different concentrations and dose schedules, explains Deborah Evans, Superintendent Pharmacist […]
Deborah Evans is superintendent pharmacist and clinic director at Remedi Health, an independent pharmacy and healthcare clinic in Winchester. Remedi Health runs a weight management service and has […]
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.
